Venmax Drugs and Pharmaceuticals Advances Merger Process

Venmax Drugs and Pharmaceuticals Ltd held a mandatory meeting of its equity shareholders on October 24, 2026. The meeting followed an order by the NCLT, Hyderabad Bench-II, dated September 7, 2026.

Reader Takeaway: Shareholders convened to vote on the Hatri Pharma merger; final approval results are pending official disclosure.

What just happened

Venmax Drugs facilitated a meeting to secure shareholder approval for the Scheme of Amalgamation with Hatri Pharma Private Limited. The session was conducted in a hybrid format, allowing for both physical attendance and virtual participation via Video Conferencing or Other Audio-Visual Means. Managing Director Mr. Venkata Rao Sadhanala presented the strategic rationale, objectives, and share exchange ratios for the merger to the attending members.

The process

The company utilized CDSL’s remote e-voting platform between October 21 and October 23, 2026. Shareholders who did not exercise their right to vote electronically were provided the opportunity to cast their ballots during the meeting. Ms. Sarvani Desiraju, appointed by the NCLT, chaired the proceedings, while Ms. Kruthi Kalaga acted as the independent Scrutinizer responsible for overseeing the voting process and collating the results.

What to track next

The primary focus for investors is the forthcoming release of the Scrutinizer's final report. Once the results are finalized, the company will announce the official outcome of the voting process. This disclosure is expected to be uploaded to the official websites of the company and the BSE, confirming whether the required majority consent for the amalgamation has been secured.